PTAB To Review Claims In Novartis' Dementia Patch Patents

Law360, New York (October 15, 2014, 5:20 PM EDT) -- The U.S. Patent and Trademark Office’s patent appeal board opted Tuesday to institute inter partes reviews of two Novartis AG patents covering its dementia treatment patch Exelon, finding petitioner Noven Pharmaceuticals Inc. had shown a reasonable likelihood of prevailing on its challenged claims.

A three-judge panel of the USPTO’s Patent Trial and Appeal Board found that Noven, a subsidiary of Japan-based Hisamitsu Pharmaceutical Co. Inc., had shown a reasonable chance of proving seven claims in U.S. Patent No. 6,335,031 B1 and that six claims in U.S....
To view the full article, register now.